| Medical and Health Sciences | Lifetime | 991 | ES 12 | 99.95 |
| Medical and Health Sciences | 2021-2025 | 58 | ES 3 | 99.99 |
| Nephrology | Lifetime | 25 | ES 1 | 99.79 |
| Medical Physiology | Lifetime | 879 | ES 15 | 98.36 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 770 | ES 9 | 97.29 |
| Immunology | Lifetime | 858 | ES 8 | 97.18 |
| Pathology and Forensic Medicine | Lifetime | 834 | ES 16 | 95.97 |
| Transplantation | Lifetime | 503 | ES 16 | 76.39 |
| Nephrology | 2021-2025 | 3 | ES 1 | 99.93 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 45 | ES 1 | 99.47 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 240 | ES 3 | 98.12 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 289 | ES 6 | 97.43 |
| Surgery | 2021-2025 | 647 | ES 6 | 94.40 |
| Infectious Diseases | 2021-2025 | 319 | ES 8 | 94.03 |
| Medical Physiology | 2021-2025 | 453 | ES 16 | 93.54 |
| Immunology | 2021-2025 | 410 | ES 5 | 88.45 |
| Nutrition and Dietetics | 2021-2025 | 268 | ES 5 | 90.31 |
| Transplantation | 2021-2025 | 67 | ES 5 | 87.26 |
| Rheumatology | 2021-2025 | 374 | ES 6 | 84.94 |
| Pathology and Forensic Medicine | 2021-2025 | 453 | ES 12 | 80.72 |
| Genetics | 2021-2025 | 698 | ES 14 | 78.65 |
| Hematology | 2021-2025 | 432 | ES 4 | 67.48 |
| Health Informatics | 2021-2025 | 226 | ES 4 | 47.18 |
| Biomedical Research and Pathophysiology | Lifetime | 9 | ES 1 | 99.35 |
| Chronic Kidney Disease and Diabetes | Lifetime | 30 | ES 1 | 99.75 |
| Dialysis and Renal Disease Management | Lifetime | 46 | ES 1 | 99.65 |
| Acute Kidney Injury Research | Lifetime | 26 | ES 1 | 99.53 |
| Renal Diseases and Glomerulopathies | Lifetime | 61 | ES 3 | 99.50 |
| Phagocytosis and Immune Regulation | Lifetime | 30 | ES 1 | 99.16 |
| COVID-19 Clinical Research Studies | Lifetime | 200 | ES 3 | 99.00 |
| Lysosomal Storage Disorders Research | Lifetime | 49 | ES 1 | 99.00 |
| Cell death mechanisms and regulation | Lifetime | 102 | ES 2 | 99.06 |
| Diabetes Treatment and Management | Lifetime | 338 | ES 1 | 98.70 |
| Parathyroid Disorders and Treatments | Lifetime | 221 | ES 3 | 98.44 |
| Renal and related cancers | Lifetime | 443 | ES 4 | 97.91 |
| Blood Pressure and Hypertension Studies | Lifetime | 600 | ES 7 | 98.30 |
| Glycogen Storage Diseases and Myoclonus | Lifetime | 129 | ES 8 | 97.54 |
| Healthcare cost, quality, practices | Lifetime | 210 | ES 2 | 97.09 |
| NF-κB Signaling Pathways | Lifetime | 326 | ES 3 | 96.94 |
| COVID-19 and healthcare impacts | Lifetime | 699 | ES 22 | 93.34 |
| Muscle and Compartmental Disorders | Lifetime | 203 | ES 3 | 96.01 |
| Renal Transplantation Outcomes and Treatments | Lifetime | 969 | ES 24 | 96.81 |
| Potassium and Related Disorders | Lifetime | 208 | ES 3 | 96.05 |
| Biomarkers in Disease Mechanisms | Lifetime | 186 | ES 4 | 93.59 |
| Renal and Vascular Pathologies | Lifetime | 943 | ES 13 | 95.29 |
| Erythropoietin and Anemia Treatment | Lifetime | 348 | ES 13 | 95.00 |
| Electrolyte and hormonal disorders | Lifetime | 708 | ES 8 | 94.79 |
| Macrophage Migration Inhibitory Factor | Lifetime | 437 | ES 5 | 88.64 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 246 | ES 3 | 85.94 |
| Magnesium in Health and Disease | Lifetime | 695 | ES 16 | 85.92 |
| Connective Tissue Growth Factor Research | Lifetime | 428 | ES 10 | 83.73 |
| GDF15 and Related Biomarkers | Lifetime | 875 | ES 34 | 74.57 |
| Hypertrophic osteoarthropathy and related conditions | Lifetime | 225 | ES 5 | 63.02 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 2 | ES 1 | 99.85 |
| Dialysis and Renal Disease Management | 2021-2025 | 8 | ES 1 | 99.68 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 26 | ES 1 | 99.46 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 19 | ES 1 | 99.30 |
| Diabetes Treatment and Management | 2021-2025 | 60 | ES 1 | 99.38 |
| COVID-19 Clinical Research Studies | 2021-2025 | 389 | ES 9 | 98.16 |
| Renal and Vascular Pathologies | 2021-2025 | 40 | ES 3 | 97.68 |
| Healthcare cost, quality, practices | 2021-2025 | 35 | ES 1 | 96.04 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 277 | ES 5 | 97.19 |
| Renal Transplantation Outcomes and Treatments | 2021-2025 | 116 | ES 7 | 97.29 |
| Hormonal Regulation and Hypertension | 2021-2025 | 73 | ES 2 | 96.63 |
| COVID-19 and healthcare impacts | 2021-2025 | 397 | ES 7 | 93.78 |
| Electrolyte and hormonal disorders | 2021-2025 | 45 | ES 3 | 95.06 |
| Renal and related cancers | 2021-2025 | 145 | ES 3 | 95.61 |
| Heart Failure Treatment and Management | 2021-2025 | 370 | ES 19 | 95.48 |
| Ion Transport and Channel Regulation | 2021-2025 | 39 | ES 1 | 92.95 |
| Parathyroid Disorders and Treatments | 2021-2025 | 174 | ES 10 | 94.14 |
| Potassium and Related Disorders | 2021-2025 | 60 | ES 3 | 95.06 |
| Biomedical Research and Pathophysiology | 2021-2025 | 29 | ES 2 | 91.22 |
| Acute Kidney Injury Research | 2021-2025 | 205 | ES 2 | 92.00 |
| Global Health Care Issues | 2021-2025 | 346 | ES 10 | 87.82 |
| Pancreatic function and diabetes | 2021-2025 | 568 | ES 5 | 91.42 |
| Genetic and Kidney Cyst Diseases | 2021-2025 | 179 | ES 4 | 87.45 |
| Lysosomal Storage Disorders Research | 2021-2025 | 266 | ES 4 | 88.95 |
| GDF15 and Related Biomarkers | 2021-2025 | 89 | ES 7 | 84.13 |
| Organ Donation and Transplantation | 2021-2025 | 385 | ES 20 | 87.93 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 893 | ES 27 | 84.59 |
| Sodium Intake and Health | 2021-2025 | 274 | ES 6 | 80.68 |
| Phagocytosis and Immune Regulation | 2021-2025 | 409 | ES 7 | 76.49 |
| Genetic Syndromes and Imprinting | 2021-2025 | 380 | ES 14 | 74.76 |
| Neurological and metabolic disorders | 2021-2025 | 225 | ES 7 | 70.22 |
| Muscle and Compartmental Disorders | 2021-2025 | 349 | ES 20 | 67.76 |
| General Medical Therapies and Clinical Treatment Research | 2021-2025 | 71 | ES 22 | 71.72 |
| Cell death mechanisms and regulation | 2021-2025 | 383 | ES 5 | 63.26 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 549 | ES 19 | 63.68 |
| Renal function and acid-base balance | 2021-2025 | 579 | ES 12 | 60.05 |
| Renin-Angiotensin System Studies | 2021-2025 | 411 | ES 14 | 54.74 |
| Neurological Complications and Syndromes | 2021-2025 | 882 | ES 13 | 49.91 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 722 | ES 19 | 44.26 |
| Connective Tissue Growth Factor Research | 2021-2025 | 235 | ES 10 | 37.84 |
| Apelin-related biomedical research | 2021-2025 | 723 | ES 12 | 33.95 |
